Merck's Pancreatic Cancer Treatment Gets FDA Nod

Health and Healthcare

Published: October 16, 2018 10:15 am

Last Updated: January 11, 2020 4:22 pm

Merck & Co. Inc. (NYSE: MRK) shares were up handily on Tuesday after the company announced a key update from the U.S. Food and Drug Administration (FDA). The agency granted orphan drug designation for Lynparza (olaparib) for the treatment of pancreatic cancer.

Lynparza is currently being investigated as maintenance therapy in patients with germline BRCA-mutated metastatic pancreatic cancer whose disease has not progressed following first-line platinum-based chemotherapy.

For some quick background: Pancreatic cancer is a rare, life-threatening disease that accounts for about 3% of all cancers in the United States. Due to the late onset of symptoms, patients are often diagnosed after the cancer has progressed to locally advanced or metastatic stages of the disease. Five-year survival rates remain low in the United States at 8.5%.

Sean Bohen, Executive Vice President, Global Medicines Development, and chief medical officer at AstraZeneca, commented:

Pancreatic cancer is an area of significant unmet medical need. This is especially true for patients with metastatic disease, where the benefits of current treatment options are very limited.

Dr. Roy Baynes, senior vice president and head of Global Clinical Development, chief medical officer, Merck Research Laboratories, added:

Pancreatic cancer is a relatively less common, but life-threatening, form of cancer. The FDA Orphan Drug Designation reinforces the importance of our collaboration in bringing Lynparza to patients in need.

Shares of Merck were last seen up about 1% at $70.11 on Tuesday, with a consensus analyst price target of $75.99 and a 52-week trading range of $52.83 to $72.89.

24/7 Wall St.
Why Software Stocks May Be the Best Q4 Buys Now

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.